CDC panel unanimously recommends new RSV antibody treatment for infants and high-risk toddlers

A CDC advisory panel recommended that all infants under 8 months old receive a new RSV antibody treatment called nirsevimab or Beyfortus.
The antibody shot provides months of protection by directly delivering RSV antibodies into a baby's bloodstream.
Children 8-19 months old with health conditions may receive a second dose for added protection in their second RSV season.
The preventive shot aims to reduce respiratory infections, hospitalizations, and deaths from RSV in infants and toddlers.
Logistical challenges remain in distributing the treatment ahead of RSV season, but it will be free for eligible children through federal programs.